Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 5, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2014-05-16
DOI
10.3389/fimmu.2014.00206
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Pituitary autoimmunity in patients with diabetes mellitus and other endocrine disorders
- (2014) I. Lupi et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
- (2013) Jedd D. Wolchok et al. Annals of the New York Academy of Sciences
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Checkpoint blocking antibodies in cancer immunotherapy
- (2013) Chrisann Kyi et al. FEBS LETTERS
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy
- (2013) Margaret K. Callahan et al. JOURNAL OF LEUKOCYTE BIOLOGY
- At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy
- (2013) Andrew M. Intlekofer et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- Cutaneous melanoma
- (2013) Alexander MM Eggermont et al. LANCET
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Enhanced Autoimmunity Associated with Induction of Tumor Immunity in Thyroiditis-Susceptible Mice
- (2013) Suresh Kari et al. THYROID
- PD-1 Inhibitor Becomes "Breakthrough Therapy"
- (2013) Cancer Discovery
- Following up tumor-specific regulatory T cells in cancer patients
- (2013) Laurence Zitvogel et al. OncoImmunology
- HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients
- (2013) Hans-Henning Schmidt et al. OncoImmunology
- Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
- (2012) Maria Grazia Ruocco et al. JOURNAL OF CLINICAL INVESTIGATION
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
- (2012) F. Torino et al. ONCOLOGIST
- Autoimmunity associated with immunotherapy of cancer
- (2011) S. M. Amos et al. BLOOD
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
- (2011) R. R. Huang et al. CLINICAL CANCER RESEARCH
- Identification of TPIT and other novel autoantigens in lymphocytic hypophysitis; immunoscreening of a pituitary cDNA library and development of immunoprecipitation assays
- (2011) Casey Jo Anne Smith et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- Thyroid Dysfunction from Antineoplastic Agents
- (2011) O.-P. R. Hamnvik et al. JNCI-Journal of the National Cancer Institute
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsy-proven IgG4-related hypophysitis
- (2011) M. A. Landek-Salgado et al. Pituitary
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Control of Th2-Mediated Inflammation by Regulatory T Cells
- (2010) K. Venuprasad Poojary et al. AMERICAN JOURNAL OF PATHOLOGY
- Opportunistic autoimmune disorders
- (2010) Yi-chi M. Kong et al. Annals of the New York Academy of Sciences
- Improved Endpoints for Cancer Immunotherapy Trials
- (2010) A. Hoos et al. JNCI-Journal of the National Cancer Institute
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Autoimmune thyroiditis as an indicator of autoimmune sequelae during cancer immunotherapy
- (2009) Yi-chi M. Kong et al. AUTOIMMUNITY REVIEWS
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
- Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts
- (2009) C. Jandus et al. CANCER RESEARCH
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- Naturally-existing CD4+CD25+Foxp3+ regulatory T cells are required for tolerance to experimental autoimmune thyroiditis induced by either exogenous or endogenous autoantigen
- (2009) Gerald P. Morris et al. JOURNAL OF AUTOIMMUNITY
- Autoimmune thyroiditis: A model uniquely suited to probe regulatory T cell function
- (2009) Yi-chi M. Kong et al. JOURNAL OF AUTOIMMUNITY
- Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma
- (2009) Andreas Bonertz et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor Regression following DNA Vaccination and Regulatory T Cell Depletion in neu Transgenic Mice Leads to an Increased Risk for Autoimmunity
- (2009) J. B. Jacob et al. JOURNAL OF IMMUNOLOGY
- No Correlation Between Clinical Response to CTLA-4 Blockade and Presence of NY-ESO-1 Antibody in Patients With Metastatic Melanoma
- (2009) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR–induced stop signal
- (2009) Brian T Fife et al. NATURE IMMUNOLOGY
- Pituitary autoimmunity: 30 years later
- (2008) Patrizio Caturegli et al. AUTOIMMUNITY REVIEWS
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
- Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis
- (2008) J.-M. Choi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started